Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository

Sevim, Ecem; Zisa, Diane; Andrade, Danieli; Sciascia, Savino; Pengo, Vittorio; Tektonidou, Maria G; Ugarte, Amaia; Gerosa, Maria; Belmont, H. Michael; Zamorano, Maria Angeles Aguirre; Fortin, Paul R; Ji, Lanlan; Efthymiou, Maria; Cohen, Hannah; Branch, D. Ware; Jesús, Guilherme Ramires de; Andréoli, Laura; Petri, Michelle; Rodríguez, Esther; Cervera, Ricard; Knight, Jason S.; Atsumi, Tatsuya; Roubey, Robert; Bertolaccini, Maria Laura; Erkan, Doruk; Barbhaiya, Medha; Investigators, Aps Action

doi:10.1002/acr.24468

Cited by 44 publications

(51 citation statements)

References 49 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The baseline characteristics of aPL-positive patients enrolled in the international registry have been described [9], focusing on overall features and clinical and laboratory subtypes. At the time of the analysis in 2019, more than 800 aPLpositive patients (mean age: 45 ± 13 years; female: 74%; white 68%) were included.…”

Section: Aps Action Clinical Database and Repository ("Registry")mentioning

confidence: 99%

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose of Review APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions. Recent Findings APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. Summary APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients.

show abstract

Section: Aps Action Clinical Database and Repository ("Registry")mentioning

confidence: 99%

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Antiphospholipid antibodies (APLAs) are biomarkers of a spectrum of clinical features observed in antiphospholipid syndrome (APS). 1 Features of APS include venous and arterial thrombosis involving multiple organs and having various presentations. 1 APLAs that are components of APS criteria include IgG and/or IgM anticardiolipin (aCL), anti-β2-glycoprotein1 (anti-β2GP1) and the 'lupus anticoagulant' (LAC).…”

Section: Introductionmentioning

confidence: 99%

“…1 Features of APS include venous and arterial thrombosis involving multiple organs and having various presentations. 1 APLAs that are components of APS criteria include IgG and/or IgM anticardiolipin (aCL), anti-β2-glycoprotein1 (anti-β2GP1) and the 'lupus anticoagulant' (LAC). 2 Other non-criteria APLA such as antiphosphatidylserine/prothrombin (PS/PT) complex, anti-PT and antidomain 1 of β2-GP1 have also found a diagnostic niche in APS.…”

Section: Introductionmentioning

confidence: 99%

Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients

et al. 2021

View full text Add to dashboard Cite

BackgroundReports of severe COVID-19 being associated with thrombosis, antiphospholipid antibodies (APLA), and antiphospholipid syndrome have yielded disparate conclusions. Studies comparing patients with COVID-19 with contemporaneous controls of similar severity are lacking.Methods22 COVID-19+ and 20 COVID-19– patients with respiratory failure admitted to intensive care were studied longitudinally. Demographic and clinical data were obtained from the day of admission. APLA testing included anticardiolipin (aCL), anti-β2glycoprotien 1 (β2GP1), antidomain 1 β2GP1 and antiphosphatidyl serine/prothrombin complex. Antinuclear antibodies (ANAs) were detected by immunofluorescence and antibodies to cytokines by a commercially available multiplexed array. Analysis of variance was used for continuous variables and Fisher’s exact test was used for categorical variables with α=0.05 and the false discovery rate at q=0.05.ResultsAPLAs were predominantly IgG aCL (48%), followed by IgM (21%) in all patients, with a tendency towards higher frequency among the COVID-19+. aCL was not associated with surrogate markers of thrombosis but IgG aCL was strongly associated with worse disease severity and higher ANA titres regardless of COVID-19 status. An association between aCL and anticytokine autoantibodies tended to be higher among the COVID-19+.ConclusionsPositive APLA serology was associated with more severe disease regardless of COVID-19 status.Trial registration numberNCT04747782

show abstract

Section: Introductionmentioning

confidence: 99%

“…Anti-phospholipid antibodies (APLA) are biomarkers of a spectrum of clinical features observed in anti-phospholipid syndrome (APS) 1 . Features of APS include venous and arterial thrombosis involving multiple organs and having various presentations 1 . APLA that are components of APS criteria include IgG and/or IgM anti-cardiolipin (aCL), -β2-glycoprotein1 (GP1), and the “lupus anticoagulant” (LAC) 2 .…”

Section: Introductionmentioning

confidence: 99%

Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and negative patients

Trahtemberg

Rottapel

DosSantos

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Reports of severe COVID-19 being associated with thrombosis, anti-phospholipid antibodies (APLA), anti-phospholipid syndrome (APS) have yielded disparate conclusions. Studies comparing COVID-19 patients with contemporaneous controls of similar severity are lacking. Methods: 22 COVID+ and 20 COVID- patients with respiratory failure admitted to intensive care were studied longitudinally. Demographic and clinical data were obtained from the day of admission. APLA testing included anti-cardiolipin (aCL), anti-β2glycoprotein 1 (β2GP1), anti-domain 1 β2 glycoprotein 1 (β2GP1) and anti-phosphatidyl serine/prothrombin complex (PS/PT). Anti-nuclear antibodies (ANA) were detected by immunofluorescence and antibodies to cytokines by a commercially available multiplexed array. ANOVA was used for continuous variables and Fisher exact test was used for categorical variables with α=0.05 and the false discovery rate at q=0.05. Results: APLA were predominantly IgG aCL (48%) followed by IgM (21%) in all patients, with a tendency toward higher frequency among the COVID+. aCL was not associated with surrogate markers of thrombosis but IgG aCL was strongly associated with worse disease severity and higher ANA titers regardless of COVID-19 status. An association between aCL and anti-cytokine autoantibodies tended to be higher among the COVID+ cohort. Conclusions: Positive APLA serology was associated with more severe disease regardless of COVID-19 status.

show abstract

Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository

Abstract: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as

Cited by 44 publications

References 49 publications

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients

Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and negative patients

Contact Info

Product

Resources

About